

CORRECTION

Open Access



# Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

Kosuke Ebina<sup>1\*</sup>, Motomu Hashimoto<sup>2</sup>, Wataru Yamamoto<sup>2,3</sup>, Toru Hirano<sup>4</sup>, Ryota Hara<sup>5</sup>, Masaki Katayama<sup>6</sup>, Akira Onishi<sup>7</sup>, Koji Nagai<sup>8</sup>, Yonsu Son<sup>9</sup>, Hideki Amuro<sup>9</sup>, Keiichi Yamamoto<sup>10</sup>, Yuichi Maeda<sup>4</sup>, Koichi Murata<sup>2</sup>, Sadao Jinno<sup>7</sup>, Tohru Takeuchi<sup>8</sup>, Makoto Hirao<sup>1</sup>, Atsushi Kumanogoh<sup>4</sup> and Hideki Yoshikawa<sup>1</sup>

## Correction to: *Arthritis Res Ther*

<https://doi.org/10.1186/s13075-019-1880-4>

Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.

In Fig. 1b, the heading should read: Adjusted survival due to lack of effectiveness

In Fig. 2b, the heading should read: Adjusted survival due to toxic adverse events

In addition, the authors would like to update the legends of Figure 1, 2, 3 and 4 to the following:

Fig. 1 Drug survival rates due to lack of effectiveness in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 2 Drug survival rates due to toxic adverse events in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN =

etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 3 Drug survival rates due to remission in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 4 Overall drug survival rates (excluding non-toxic reasons and remission) in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

The publishers apologise for the errors. The corrected figures are given below:

\* Correspondence: [k-ebina@umin.ac.jp](mailto:k-ebina@umin.ac.jp)

<sup>1</sup>Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan

Full list of author information is available at the end of the article



**Author details**

<sup>1</sup>Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan. <sup>2</sup>Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan. <sup>3</sup>Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan. <sup>4</sup>Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan. <sup>5</sup>The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan. <sup>6</sup>Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan. <sup>7</sup>Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan. <sup>8</sup>Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan. <sup>9</sup>First Department of Internal Medicine, Kansai Medical University, Osaka, Japan. <sup>10</sup>Department of Medical Informatics, Wakayama Medical University Hospital, Wakayama, Japan.


Received: 15 April 2019 Accepted: 15 April 2019

Published online: 06 May 2019

**Reference**

1. Ebina, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. *Arthritis Res Ther.* 2019;21:91 <https://doi.org/10.1186/s13075-019-1880-4>.


**a** Non-adjusted survival due to lack of effectiveness



Number at risk

ABT	681	536	472	414	365	293	229	181
ADA	558	419	361	308	266	231	190	168
CZP	229	164	142	131	101	77	50	26
ETN	891	694	629	580	531	476	418	384
GLM	464	342	296	239	191	162	138	120
IFX	748	641	580	501	440	390	352	322
TCZ	895	709	613	548	461	412	350	302

**b** Adjusted survival due to lack of effectiveness



Number at risk

ABT	632	512	454	399	351	284	223	175
ADA	458	360	308	257	228	199	166	145
CZP	214	155	135	124	95	72	46	23
ETN	729	577	523	484	443	401	352	321
GLM	434	329	286	233	188	160	136	118
IFX	564	487	438	374	331	288	257	232
TCZ	752	623	536	477	397	353	296	251

**Fig. 1** Drug survival rates due to lack of effectiveness in **a** non-adjusted cases and **b** adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

